MMP inhibitory monoclonal antibodies targeting MMP-9 or -14 demonstrated promising anti-tumor activities in preclinical models of breast cancer and may exhibit clinical benefits in cancer patients without significant toxicity in clinical trials. This evidence concerns the gene MMP9 and neoplasm.